CYTOGENETIC RESPONSE TO IMATINIB MESYLATE (GLIVEC) THERAPY IN CHRONIC MYELOID LEUKAEMIA

Authors

  • Faiza Fahim
  • Helen Mary Robert
  • Kashif Sheikh
  • Suhaib Ahmed

Abstract

Objective: To analyze the cytogenetic response to Imatinib Mesylate (Glivec) therapy in patients of Chronic Myeloid Leukemia (CML).

Study Design: Descriptive.

Place and Duration of Study: This study was conducted at Armed Forces Institute of Pathology (AFIP) for a period of one year from Dec 2010 – Dec 2011.

Patients and Methods: 26 patients of CML were included in the study who were diagnosed on bone marrow examination. All the patients included, had their cytogenetic studies done for Philadelphia (Ph) chromosomes and were positive. These patients were put on Glivec therapy 400 mg once daily after diagnosis. Out of the 26 patients 24 were in chronic phase of CML while two were diagnosed to be in the accelerated one. The bone marrow was cultured by a modification of the method Moorhead et al l in GIBCO blood culture medium. Slides were stained by Giemsa stain. The trypsin G banding preparation were made by Sea bright technique. At least 20 metaphases from each specimen were analyze for Ph chromosomes positivity. After Glivec therapy cytogenetic analysis was carried out for responses which categorized as major, minor and absent cytogenetic response as laid down by defined criteria.

Results: Out of the 26 patients included in the study 23% were females while 77% were males. The median age was 40 years (range 17-52 years). 8% patients were in the accelerated while 92% patients included in the study were in the chronic phase of CML. 50% patients had a partial Cytogenetic Response(CR), 30% had a minor CR while 19.2% had no CR.

Conclusions: The effectiveness of Imatinib Mesylate (Glivec) therapy can be determined by the performing Cytogenetic analysis and determining of the underlying responses. The cytogenetic clonal evolution predicts the outcomes in patients in accelerated phase of CML. The results should be considered in the selection of particular therapies in relation to dose escalation of Glivec.

Keywords: Chronic myeloid leukemia, Cytogenetic response, Imatinib mesylate

Downloads

Published

03-08-2016

How to Cite

1.
Fahim F, Robert HM, Sheikh K, Ahmed S. CYTOGENETIC RESPONSE TO IMATINIB MESYLATE (GLIVEC) THERAPY IN CHRONIC MYELOID LEUKAEMIA. Pak J Pathol [Internet]. 2016 Aug. 3 [cited 2024 Mar. 28];24(3). Available from: https://pakjpath.com/index.php/Pak-J-Pathol/article/view/94

Issue

Section

Articles